A round-up of HbA1c sigma-metrics - Westgard QC

Tools, Technologies and Training for Healthcare Laboratories

A round-up of HbA1c sigma-metrics

A review of some recent Sigma-metrics of HbA1c methods and instruments. HbA1c is one of the success stories of standardization and analytical performance specification evolution. Yet the success appears to be fleeting. Despite knowing how good performance should be, instruments are not consistently achieving the required quality.

A Round-Up of HbA1c Sigma metrics

November 2026
Sten Westgard, MS

This is meant to accompany our guest article on HbA1c, PT and Sigma metrics.

A little over a year ago, Erna Lenters-Westra published an interesting update on the state of quality of HbA1c POC devices:

Challenges in Hb A1c Point-of-Care Testing: Only 5 of 19 Hb A1c Point-of-Care Devices Meet IFCC and NGSP Certification Criteria on Independent Evaluation. May 2025 Clinical Chemistry 71(7):775-788 DOI: 10.1093/clinchem/hvaf059 Erna Lenters-Westra, Priyanka Singh, Beatrice Vetter, Emma English.

"Overall, these results are very concerning, as good analytical performance is essential for effective clinical care of people with diabetes or when identifying those at risk of diabetes. While one device showed performance that met the sigma metric criteria for use in clinical trials (>4σ) and 9 devices met the sigma metric criteria for use in routine methods (>2σ), many could not be recommended for use in settings where POCT may be the only available and affordable option, as is the case for many LMICs."[Low- to Middle- Income Countries]

Lots of HbA1c studies are being published all the time. If we take a few of them using the CLIA 2025 goal of 8% as well as the NGSP goal of 6%, we find a variable state of performance around the world. [Remember, there was a debate over the right goals for HbA1c as CLIA updated their goals. In 2022, they proposed 10%, NGSP wanted 6%, CLIA compromised on 8%]

Let's start with a study that looked at both the cobas c501 and the Adams HA-8180V in Turkey: 

Impact of ISO/TS 20914-based measurement uncertainty on HbA1c classification around clinical decision limits: A real-world evaluation of two analytical systems. Ahmet Burak Gurpinar, Canan Karadag, Muzaffer Katar. Clinical Chimica Acta 594 (2027) 122868.

This study looked at both the cobas c501 and the Adams HA-8180V HbA1c methods.

 

2026 11 15 cobas c501 TEa6 NMEDx

2026 11 15 Adams HA 8180V TEa8 NMEDx

2026 11 15 Adams HA 8180V TEa6 NMEDx

Here in the US, another study looked at the new Tosoh GR01:

Comparison of Two Ion-Exchange HPLC Methods for HbA1c Quantitation. Darren L. Latzig, Paula Zwiefelhofer, Ian L. Gunsolus. The Journal of Applied Laboratory Medicine, Volume 11, Issue 6, November 2026, Pages 1452–1462, https://doi.org/10.1093/jalm/jfag112

This study looked at four levels of whole blood and 4 levels hemosylate:

2026 11 15 Tosoh GR01 TEa 8 NMEDx 

2026 11 15 Tosoh GR01 TEa 6 nmed 2

Another study looked at the Bio-Rad D-10 in Gujarat, India:

Sigma metric and Quality Goal Index assessment of hemoglobin A1c analytical performance in an ambulatory accredited laboratory. Jagdish Chandarana, Kinhal Butani. Laboratory Medicine, 2026, 57(5), lmag052 https://doig.org/10.1093/labmed/lmag052.

This assessed long-term imprecision at high and low and one level of bias from the QC target:

2026 11 15 D10 India TE8 nmedx 

2026 11 15 D10 India TE6 nmedx

Finally, another study of the Bio-Rad D-10, this time in Malaysia:

Evaluation of the HbA1c Analytical Performance on the Bio-Rad D-10 Analyzer Using Sigma Metrics at the Clinical Diagnostic Laboratory, USM Medical Centre Bertam. J of Biomed & Clin Sci, Dec 2025, 10(2), 46-53.

This assessed 7 months of data on QC, with bias determined from the peer group mean:

2026 11 15 D10 Malaysia TE8 nmedx

2026 11 15 D10 Malaysia TE6 nmedx

So what do we see? Sigma metrics are not the same on every device or in every location. Also, the TEa goal of 6% is not really achievable. CLIA's choice of 8% seems to be something that some labs, some devices can achieve. 

For all the effort that has been expended to bring us to this moment, we still have a long way to go. We have pockets of success, but reliable performance for the majority eludes us.

 

 

 

Let us know what you're interested in!

Please use this form to request more information about.

Westgard Products and Services.

Invalid Input
Invalid Input
Invalid Input
Invalid Input